Is Sermorelin Legal in Maryland? How Women Can Access It Safely

What Sermorelin Is and Why Women Are Asking About It

Sermorelin is a synthetic 29-amino-acid peptide that mimics the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It signals the pituitary gland to produce and secrete growth hormone (GH) in a pulsatile, physiologically normal pattern. That is meaningfully different from injecting synthetic GH directly, because the pituitary's own feedback loops stay intact.

Women ask about sermorelin for a specific reason: GH secretion declines with age in both sexes, but the trajectory in women is shaped by estrogen. Estrogen amplifies GH pulsatility, so as estrogen falls during perimenopause and post-menopause, GH amplitude drops faster than many clinicians expect. A woman in her late 40s may have GH secretion patterns closer to those of a 65-year-old man. That biology is why the interest in GHRH-based peptides among women has grown alongside menopause awareness.

The conditions where sermorelin is discussed in women's health include:

• Perimenopause and post-menopause (declining GH, sleep disruption, body composition shifts)
• PCOS (altered GH-IGF-1 axis, insulin resistance)
• Hypothalamic amenorrhea and functional hypothalamic dysfunction
• Female pattern fat redistribution and lean mass loss
• Fatigue syndromes evaluated after thyroid and sex-hormone optimization

How Sermorelin Differs from Direct Growth Hormone

Synthetic recombinant human GH (rhGH, brand name Norditropin, Genotropin, others) is FDA-approved for adult GH deficiency but carries a higher risk profile, suppresses natural GH secretion, and is substantially more expensive. Sermorelin, by stimulating endogenous GH, keeps the pituitary responsive and does not carry the same level of regulatory restriction on prescribing indications. This distinction matters for legal access, which is discussed in detail below.

The Federal Legal Framework: FDA Status of Sermorelin

Sermorelin is a named, approved active pharmaceutical ingredient. The FDA approved sermorelin acetate for injection under the brand name Geref in 1997 for the treatment of idiopathic growth hormone deficiency in children. Geref was voluntarily withdrawn from the US market in 2008 for commercial reasons, not safety reasons, and no branded version is currently marketed.

Because the branded product is gone, sermorelin is now dispensed almost exclusively through compounding pharmacies. The FDA's position on compounded sermorelin has shifted over time and deserves a candid explanation.

The FDA Bulk Drug Substances List

The FDA regulates compounded drugs under Section 503A (traditional compounding pharmacies) and Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. Compounding pharmacies may only use drug substances that are on the FDA's approved bulk drug substances list, or that are components of an FDA-approved drug, or that meet specific criteria for the 503A or 503B nominated substances list.

Sermorelin has been nominated to the FDA's 503A bulk drug substances list and, as of this writing, remains in a Category 2 status, meaning the FDA has not yet completed its evaluation of whether it may be compounded under 503A. This creates a federal gray area: technically, a 503A pharmacy compounding sermorelin is operating without explicit FDA clearance of the substance under the new framework, but enforcement has been minimal and the substance is not on the FDA's "do not compound" list.

503B outsourcing facilities have a separate pathway and some have been able to compound sermorelin under clinical need justification. The legal and regulatory picture is genuinely unsettled at the federal level. This is not a state-specific Maryland issue. Any clinician or telehealth platform telling you sermorelin is "fully FDA-cleared for compounding" is overstating the current federal status. Honest patient counseling acknowledges the ambiguity.

Maryland State Law: Is Sermorelin Legal Here?

Maryland does not have a specific state law banning sermorelin. The state regulates compounding pharmacies through the Maryland Board of Pharmacy, which follows federal USP standards and the state's pharmacy practice act. Licensed Maryland compounding pharmacies that operate as 503A facilities must comply with USP 797 standards for sterile compounding, and any that compound sermorelin are operating within the same federal gray zone described above.

From a medical practice standpoint, Maryland-licensed physicians, nurse practitioners, and physician assistants may prescribe compounded sermorelin as part of individualized patient care under the state's medical practice act, as long as the prescription is for a legitimate medical purpose and the prescribing clinician has established a valid patient-clinician relationship. There is no Maryland statute or Board of Medicine opinion that specifically prohibits sermorelin prescribing.

What "Legal in Maryland" Actually Means in Practice

Legal access in Maryland means all of the following are true:

• A licensed Maryland clinician (MD, DO, NP, or PA with prescribing authority) has evaluated you in person or via a valid telehealth encounter
• The clinician has documented a clinical indication supported by labs (typically IGF-1, fasting insulin, sex hormones, thyroid)
• The prescription is sent to a licensed Maryland 503A compounding pharmacy or to an FDA-registered 503B outsourcing facility
• The pharmacy compounds sermorelin under USP 797 sterile standards

Buying sermorelin from a research chemical website, a fitness supplement vendor, or any source that does not require a prescription is not legal for human use. These products are marketed as "for research purposes only" specifically to avoid FDA oversight, and their purity and potency are unverified.

How to Get a Sermorelin Prescription in Maryland

Getting a prescription involves three steps: finding a qualified prescriber, completing a clinical evaluation, and using a verified pharmacy.

Step 1: Find a Qualified Prescriber

Women in Maryland can access sermorelin prescriptions through:

• Hormone-specialized women's health clinics or integrative medicine practices in the state
• Telehealth platforms licensed in Maryland that have Maryland-licensed prescribers on staff (WomanRx operates in this model)
• OB-GYN or reproductive endocrinology practices that offer hormone optimization beyond standard HRT

The prescriber should be comfortable interpreting IGF-1 levels in women across different life stages, because IGF-1 reference ranges vary by age and sex and a result that looks "normal" for a 50-year-old man may represent relative deficiency in a perimenopausal woman whose baseline was higher when estrogen was supporting GH pulsatility.

Step 2: The Clinical Evaluation

A thorough pre-sermorelin evaluation for women includes:

| Lab or Assessment | Why It Matters for Women | |---|---| | IGF-1 (fasting, morning) | Primary marker of GH axis activity; estrogen-dependent | | IGFBP-3 | Binds IGF-1; gives context to IGF-1 result | | Fasting glucose and insulin (HOMA-IR) | GH raises glucose; baseline metabolic status matters, especially in PCOS | | Estradiol, FSH, LH | Hormonal context changes IGF-1 interpretation | | TSH, free T4 | Hypothyroidism suppresses GH axis | | Cortisol (AM) | Hypercortisolism suppresses GH | | Prolactin | Elevated prolactin inhibits GH pulsatility | | DXA or DEXA body composition | Baseline lean mass and fat mass for tracking response |

A 2001 study in the Journal of Clinical Endocrinology and Metabolism found that women on oral estrogen had significantly lower IGF-1 levels than women on transdermal estrogen at equivalent systemic doses, because oral estrogen undergoes hepatic first-pass metabolism that reduces hepatic IGF-1 production. This means if you are on oral estradiol or oral contraceptives, your IGF-1 may appear falsely low, and your clinician needs to account for the route of your estrogen when interpreting results.

Step 3: Verified Pharmacy Dispensing

Ask any prescribing clinician which pharmacy they use and whether it is:

• Licensed by the Maryland Board of Pharmacy
• Accredited by PCAB (Pharmacy Compounding Accreditation Board) or equivalent
• Operating under USP 797 for sterile injectables
• Willing to provide a certificate of analysis (CoA) for each batch

Sermorelin requires cold-chain shipping and reconstitution with bacteriostatic water. A legitimate pharmacy will provide both the lyophilized peptide and the diluent, along with written reconstitution and storage instructions.

Sermorelin Dosing in Women: What the Evidence Shows

Most clinical protocols used in women start sermorelin at 0.2 to 0.3 mg (200 to 300 mcg) by subcutaneous injection administered at night, because endogenous GH peaks during slow-wave sleep. Dosing is typically five nights per week rather than nightly, to prevent pituitary desensitization.

Women generally use lower doses than men for two reasons. First, women have greater baseline sensitivity to GHRH stimulation. Second, GH raises insulin resistance transiently, and women with PCOS or metabolic syndrome are more sensitive to that effect. Starting low and titrating based on IGF-1 response at 6 to 8 weeks is standard practice.

Life-Stage Dosing Considerations

Reproductive years (not trying to conceive): A woman in her 30s with PCOS, elevated insulin, and low IGF-1 may benefit from sermorelin as an adjunct to lifestyle and metformin, but close monitoring of fasting glucose is needed because of GH's gluconeogenic effects. GH secretion is already dysregulated in PCOS, with higher GH pulse frequency but lower amplitude; sermorelin may normalize amplitude without worsening pulse frequency.

Perimenopause: This is where clinical interest is highest. The combination of falling estrogen, disrupted sleep architecture, accelerating visceral fat gain, and declining GH pulsatility creates a biologic context where sermorelin has theoretical appeal. Controlled trials specifically in perimenopausal women are limited, which means most use in this population is extrapolated from studies in older adults. Women deserve to know that distinction.

Post-menopause: Women on transdermal hormone therapy (HRT) may see a better IGF-1 response to sermorelin than women not on HRT, because transdermal estradiol maintains hepatic IGF-1 sensitivity without the first-pass suppressive effect of oral estrogen. This has clinical implications for how you and your clinician interpret labs and adjust dose.

The WomanRx clinical team applies a three-phase framework for sermorelin monitoring in women that accounts for hormonal context:

1. Phase 1 (Weeks 1-8): Baseline labs, start at 200 mcg nightly 5x/week, recheck IGF-1 and fasting glucose at week 8. Adjust dose if IGF-1 remains below age-adjusted 50th percentile or if fasting glucose rises more than 10 mg/dL.
2. Phase 2 (Months 3-6): Body composition reassessment via DEXA or clinical measurement. Evaluate sleep quality with a validated tool (PSQI). Reassess sex hormone status. If HRT route is oral estrogen, consider switching to transdermal to optimize IGF-1 response.
3. Phase 3 (Month 6 onward): Decide on continuation, cycling (3 months on, 1 month off), or dose reduction. Annual pituitary-axis check including AM cortisol and prolactin.

Pregnancy, Lactation, and Contraception: A Required Conversation

Sermorelin is contraindicated in pregnancy. This is a non-negotiable clinical boundary, and any prescriber who does not raise it is missing a critical safety conversation.

There are no adequate human studies of sermorelin in pregnancy. Animal reproduction studies are limited. Because GH and IGF-1 are active in fetal development and placental function, introducing a pituitary stimulant during pregnancy carries theoretical teratogenic and growth-dysregulatory risk that cannot be dismissed. The FDA's labeling for Geref did not establish safety in pregnancy.

Practical rule: If you are trying to conceive, sermorelin should be stopped at least one full menstrual cycle before attempting pregnancy, and ideally discussed with a reproductive endocrinologist. If you are sexually active and not using reliable contraception, sermorelin should not be prescribed.

Lactation: There are no human lactation data for sermorelin. Peptides of its size (molecular weight approximately 3,357 Da) may transfer into breast milk, and the effect on a nursing infant's GH axis is unknown. The clinical recommendation is to avoid sermorelin during breastfeeding.

Contraception requirement: Women of reproductive age who are prescribed sermorelin should use reliable contraception throughout the course of treatment. This includes barrier methods, hormonal contraception, or an IUD. Your prescribing clinician should document this conversation in your chart.

Female-Specific Side Effects and Monitoring

Women report a different side effect profile than the male-dominated literature describes. Common effects include:

• Water retention: GH increases sodium and water retention through its effect on the kidney. Women are more sensitive to this effect hormonally, particularly in the luteal phase of the cycle. Mild swelling in the hands and feet in the first 2 to 4 weeks is common and usually self-limiting.
• Carpal tunnel symptoms: Tingling in the hands occurs in a subset of women, more often in those who are hypothyroid or perimenopausal. It typically resolves with dose reduction.
• Flushing: Distinct from hot flashes, but easy to confuse in perimenopausal women. Flushing with sermorelin tends to occur within 30 to 60 minutes of injection and lasts under an hour.
• Glucose elevation: Women with PCOS or insulin resistance need fasting glucose monitored at 4 to 6 weeks. A rise of more than 15 mg/dL warrants dose reduction or cessation.
• Injection site reactions: Mild redness and nodule formation are more common in women with lower body fat, who have less subcutaneous tissue depth.

A 2019 systematic review in Growth Hormone and IGF Research found that GH secretagogues as a class were well-tolerated in adults at physiologic doses, with water retention and glucose changes being the most clinically relevant adverse effects requiring monitoring.

Who This Is Right For (and Who Should Not Use It)

Potentially Appropriate Candidates in Women

• Perimenopausal or post-menopausal women with documented low IGF-1 (below the 25th percentile for age) and symptoms of GH decline: poor sleep, visceral fat gain, low lean mass
• Reproductive-age women with PCOS who have completed a hormonal workup and have documented GH-axis dysregulation
• Women with functional hypothalamic amenorrhea after other causes are treated, where GH axis support may aid recovery
• Women who have completed thyroid and sex-hormone optimization and still have fatigue and body composition concerns

Not Appropriate for These Women

• Pregnant women or women planning pregnancy in the near term
• Women with active cancer or a history of GH-responsive malignancy (including some breast cancers). IGF-1 is a mitogen, and the IGF-1 receptor is expressed on breast cancer cells. Women with a personal history of ER-positive breast cancer should avoid sermorelin until formal oncologic guidance is obtained.
• Women with uncontrolled diabetes or fasting glucose above 126 mg/dL
• Women with active acromegaly or Cushing syndrome
• Women with pituitary adenoma (sermorelin stimulates the same gland)
• Breastfeeding women

Evidence Gaps: What We Do and Do Not Know in Women

Women have been historically underrepresented in clinical trials of GH-axis peptides. Most of the published data on GHRH analogs and GH secretagogues comes from studies that enrolled majority-male or mixed-sex populations without sex-stratified analysis. This means several things you deserve to know:

The GHRH trial data in older adults showing improvements in slow-wave sleep and body composition enrolled both men and women, but the published results were not consistently disaggregated by sex. The improvements seen are probably real, but we cannot say with confidence how much of the effect size applies specifically to women versus men.

The interaction between sermorelin and exogenous hormones (HRT, oral contraceptives, thyroid medication) has not been studied in prospective trials. The guidance on oral vs. Transdermal estrogen and IGF-1 response is extrapolated from estrogen pharmacology research rather than sermorelin-specific trials.

No randomized controlled trial has specifically studied sermorelin in perimenopausal women as a primary population. The WomanRx editorial position is that this gap makes informed consent and careful monitoring more important, not less. A clinician who presents sermorelin to a perimenopausal woman as proven therapy, rather than as a reasonable clinical option with extrapolated evidence, is not giving you an accurate picture.

Avoiding Unregulated Sources: A Maryland-Specific Warning

Maryland residents searching for sermorelin will encounter websites selling it without a prescription, often under terms like "research peptide" or "not for human use." These sources are not legal for human use under either federal or Maryland state law. Purchasing from them carries real risks:

• Unverified purity: independent testing of gray-market peptides has found incorrect concentrations, contamination, and substituted compounds
• No clinical oversight means no dose adjustment, no safety monitoring, and no recourse if something goes wrong
• Legal risk: while personal possession charges are uncommon, buying unapproved drugs for human use carries federal risk under the FDCA

The FDA has issued multiple warning letters to peptide vendors for selling unapproved drug products. Using a licensed telehealth prescriber and a verified compounding pharmacy is the only pathway that protects both your health and your legal standing.